title: Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.
abstract: OBJECTIVE
  In 1992, we reported the first results of a randomized study in ovarian cancer, comprising two doses of cisplatin and indicated a significant difference (P = .0008) in median survival. Four years later, we now describe the results of this trial.
  
  
  METHODS
  After a median follow-up of 4 years and 9 months, 115 of 159 cases of advanced ovarian cancer, originally randomized to receive six cycles of cyclophosphamide 750 mg/m2 and either a high dose (HD) of 100 mg/m2 cisplatin or a low dose (LD) of 50 mg/m2 (LD) cisplatin, have now died.
  
  
  RESULTS
  The overall survival for HD and LD patients is 32.4% and 26.6%, respectively, and the overall relative death rate is 0.68 (P = .043). This represents a reduction in overall benefit with longer follow-up compared with the first 2 years (relative death rate of 0.52). Toxicity, particularly neurotoxicity, is still evident in the fourth year (10/31 on HD compared with 1/24 on LD).
  
  
  CONCLUSIONS
  Our recommended dose of cisplatin in combination schedule is therefore 75 mg/m2, representing the optimal balance between efficacy and toxicity.
authors.affiliation: Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, United Kingdom.
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
authors.forename: J
authors.initials: J
authors.lastname: Paul
authors.forename: J
authors.initials: J
authors.lastname: Cassidy
authors.forename: C R
authors.initials: CR
authors.lastname: Lewis
authors.forename: I D
authors.initials: ID
authors.lastname: Duncan
authors.forename: H K
authors.initials: HK
authors.lastname: Gordon
authors.forename: H C
authors.initials: HC
authors.lastname: Kitchener
authors.forename: D J
authors.initials: DJ
authors.lastname: Cruickshank
authors.forename: R J
authors.initials: RJ
authors.lastname: Atkinson
authors.forename: M
authors.initials: M
authors.lastname: Soukop
authors.forename: E M
authors.initials: EM
authors.lastname: Rankin
authors.forename: J A
authors.initials: JA
authors.lastname: Davis
authors.forename: N S
authors.initials: NS
authors.lastname: Reed
authors.forename: S M
authors.initials: SM
authors.lastname: Crawford
authors.forename: A
authors.initials: A
authors.lastname: MacLean
authors.forename: D
authors.initials: D
authors.lastname: Parkin
authors.forename: T K
authors.initials: TK
authors.lastname: Sarkar
authors.forename: J
authors.initials: J
authors.lastname: Kennedy
authors.forename: R P
authors.initials: RP
authors.lastname: Symonds
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
chemical_list: D003520:Cyclophosphamide; D002945:Cisplatin